BioNTech to Expand Vaccine Production

Company to Produce Up to 250 Million Doses in First Half of 2021

Company invests in Plasmid-Manufacturing Facility

BioNTech, the German biotechnology company that developed the first mRNA vaccine against COVID-19, has announced plans to significantly expand its vaccine production capacity. The company plans to be able to produce up to 250 million doses of its BNT162b2 vaccine in the first half of 2021.

To support its production expansion, BioNTech has invested in a new plasmid-manufacturing facility. Plasmids are circular DNA molecules that are used to produce proteins in cells. They are essential for the production of mRNA vaccines, which use mRNA to instruct cells to produce the spike protein of the SARS-CoV-2 virus.

The new plasmid-manufacturing facility will be located in Marburg, Germany. It is expected to be operational in the second half of 2021 and will have the capacity to produce enough plasmids for up to 1 billion doses of vaccine per year.

BioNTech's expansion plans are aimed at meeting the growing global demand for its vaccine. The company has already signed supply agreements with several countries, including the United States, the European Union, and the United Kingdom. The company is also working to expand its production capacity in other countries, including China and Singapore.

The expansion of BioNTech's vaccine production capacity is a positive development for the global fight against COVID-19. The company's vaccine is one of the most effective and safest vaccines available, and it is helping to protect people from the virus around the world.